Search

everythinglearnresearchcommunity

for

Search:↓

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Matriptase-2 helps control iron levels by suppressing hepcidin, and its deficiency can cause iron-deficiency anemia.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

LDL apheresis lowers inflammation and cardiovascular risk by reducing CRP levels long-term.

The NUDT15 R139C variant causes thiopurine-induced leukocytopenia through a different mechanism than previously thought in Japanese patients with inflammatory bowel disease.

Targeting lipid metabolism can help treat advanced, resistant cancers.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Adults with Tatton-Brown-Rahman syndrome may have serious heart problems and need lifelong heart monitoring.

Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

Hormone replacement therapy may lower the risk of severe COVID-19 outcomes in non-immunosuppressed people and male organ transplant recipients.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Tacrolimus is a better option than cyclosporine due to fewer side effects.

A circulating inhibitor caused insulin resistance, but clomiphene improved symptoms.

Compound 4 is a promising treatment for hair loss with low toxicity.

A specific gene variant is linked to severe insulin resistance and hormone imbalance in a teenage girl.

Clascoterone is safe for the heart, even at high doses.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.

Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.